Shuwen Biotech Reports "Multi-Million Dollar" Investment from Tasly

Shuwen Biotech, a Hangzhou diagnostics company, completed a A+ round that it described as an investment of "multi-million dollars" from Tasly Pharmaceutical Group. Shuwen aims to be the China diagnostic partner of choice for western diagnostic companies. So far, Shuwen has formed strategic partnerships with academic and commercial entities, resulting in exclusive licenses for over 20 first-in-class diagnostic technologies and 50+ patents in various medical specialties. More details.... Share this with colleagues: // //